Study of XL999 in Patients With Previously Treated Ovarian Cancer

Stopped early · Phase 2

Conditions studied: Ovarian Cancer

In brief

This clinical trial is being conducted at multiple sites to evaluate the activity, safety, and tolerability of XL999 when given weekly to patients with ovarian cancer that has previously been treated with platinum-based chemotherapy. XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.

Key facts

Study ID

NCT00277290

Run by

Symphony Evolution, Inc.

People needed

24

Starts

2006-01-01

Expected to finish

2006-11-01

Last updated by the study team

2010-02-22

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female patients with a histologically confirmed diagnosis of metastatic ovarian cancer
• Measurable disease according to Response Criteria for Solid Tumors (RECIST)
• Prior treatment with platinum-based therapy
• Platinum-sensitive or platinum-resistant disease
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Life expectancy of ≥3 months
• Adequate organ and marrow function
• Signed informed consent
• No other malignancies within 5 years

You may not qualify if…

• Radiation to ≥25% of bone marrow within 30 days of XL999 treatment
• Use of an investigational drug or cytotoxic chemotherapy within 30 days of XL999 treatment
• Prior anticancer therapy targeting VEGF (eg, bevacizumab, sorafenib, or sunitinib)
• More than two prior systemic non-platinum cytotoxic chemotherapy regimens
• Subject has not recovered to grade ≤1 or to within 10% of baseline from adverse events due to other medications administered >30 days prior to study enrollment
• History of or known brain metastases, current spinal cord compression, or carcinomatous meningitis
• Uncontrolled and/or intercurrent illness
• Patients who are pregnant or breastfeeding
• Known human immunodeficiency virus (HIV)

Where it is running

• California Cancer Care, Inc. — Greenbrae, California, United States
• Hematology/Oncology Associates of the Treasure Coast — Port Saint Lucie, Florida, United States
• University of Chicago — Chicago, Illinois, United States
• Joliet Oncology-Hematology Associates, Ltd — Joliet, Illinois, United States
• Indiana University Cancer Center — Indianapolis, Indiana, United States
• Harry and Jeanette Weinberg Cancer Institute at Franklin Square — Baltimore, Maryland, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Bradley Cohen — New City, New York, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.